Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Rowlands, Sam (2009)
Publisher: Blackwell Publishing
Languages: English
Types: Article
Subjects: RG
New technologies in both reversible contraception and sterilisation are described. The review includes recent advances in the development of oral contraception, emergency contraception, injectable contraception, vaginal rings, subdermal implants, transdermal contraception, intrauterine devices, spermicides and barrier methods. It also covers methods of transcervical female sterilisation and more easily reversible male sterilisation. The emphasis is on the technology and its safety and effectiveness. Hormonal delivery systems are described in some detail. Mention is also made of research into vaccines and male hormonal methods, where progress has been disappointing.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • (17) Anderson FD, Gibbons W, Portman D. Long-term safety of an extendedcycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. Am J Obstet Gynecol 2006; 195:92-96.
    • (18) Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74:439-445.
    • (19) Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006; 74:100-103.
    • (20) Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ ethinyl estradiol 20 microg (Loestrin 24 Fe). Contraception 2007; 75:16-22.
    • (21) Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs 2007; 67:1749-1765.
    • (22) Lakha F, Ho PC, Van der Spuy ZM, Dada K, Elton R, Glasier AF et al. A novel estrogen-free oral contraceptive pill for women: multicentre, doubleblind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Repro 2007; 22:2428-2436.
    • (23) Pei K, Xiao B, Jing X, Lu S, Wei L, Zhao H. Weekly contraception with mifepristone. Contraception 2007; 75:40-44.
    • (24) Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007; 92:3582-3589.
    • (25) Den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormonal replacement therapy use. Contraception 1999; 59:357-362.
    • (26) Glasier AF, Smith KB, Van der Spuy ZM, Ho PC, Cheng L, Dada K et al. Amenorrhoea associated with contraception: an international study on acceptability. Contraception 2003; 67:1-8.
    • (28) von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bártfai G et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360:1803- 1810.
    • (29) Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006; 108:1089-1097.
    • (30) Gemzell-Danielsson K, Marions L. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Human Reproduction Update 2004; 10:341-348.
    • (31) Novikova N, Weisberg E, Stanczyk FZ, Croxatto HB, Fraser IS. Effectiveness of levonorgestrel emergency contraception given before or after ovulation - a pilot study. Contraception 2007; 75:112-118.
    • (32) Massai MR, Forcelledo ML, Brache V, Tejada AS, Salvatierra AM, Reyes MV et al. Does meloxicam increase the incidence of anovulation induced by single administration of levonorgestrel in emergency contraception? A pilot study. Hum Repro 2007; 22:434-439.
    • (33) Pall M, Friden BE, Brannstrom M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized doubleblind study. Hum Repro 2001; 16:1323-1328.
    • (41) Sivin I, Mishell DR, Alvarez F, Brache V, Elomaa K, Lahteenmaki P et al. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1- year dose-finding trial. Contraception 2005; 71:122-129.
    • (42) Novák A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 2003; 67:187-194.
    • (43) vanden Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72:168-174.
    • (44) Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CHJ et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2005; 71:176-182.
    • (45) Ahrendt H-J, Nisand I, Bastianelli C, Gomez MA, Gemzell-Danielsson K, Urdl W et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 µg ethinyl estradiol and 3 mg of drospirenone. Contraception 2006; 74:451-457.
    • (46) Bjarnadóttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002; 186:389-395.
    • (47) Oddson K, Leifels-Fischer B, Wiel-Masson D, de Melo NR, Benedetto C, Verhoeven CH et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30mcg ethinylestradiol and 150mcg levonorgestrel: a randomized trial. Hum Repro 2005; 20:557-562.
    • (48) Roumen FJME, op ten Berg MMT, Hoomans EHM. The combined contraceptive ring (NuvaRing): first experience in daily clinical practice in the Netherlands. European Journal of Contraception & Reproductive Health Care 2006; 11:14-22.
    • (49) Merki-Feld GS, Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages. European Journal of Contraception & Reproductive Health Care 2007; 12:240-247.
    • (50) Massai R, Quinteros E, Reyes MV, Caviedes R, Zepeda A, Montero JC et al. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception 2005; 72:352-357.
    • (51) Brache V, Mishell DR, Lahteenmaki P, Alvarez F, Elomaa K, Jackanicz T et al. Ovarian function during use of vaginal rings delivering three different doses of Nestorone®. Contraception 2001; 63:257-261.
    • (53) Sivin I, Campodonico I, Kiriwat O, Holma P, Diaz S, Wan L et al. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study. Hum Repro 1998; 13:3371-3378.
    • (54) Newton J, Newton P. Implanon® - the single-rod subdermal contraceptive implant. J Drug Eval 2003; 1:181-218.
    • (55) Sivin I, Croxatto H, Bahamondes L, Brache V, Alvarez F, Massai R et al. Two-year performance of a nestorone-releasing contraceptive implant: a three-center study of 300 women. Contraception 2004; 69:137-144.
    • (56) Barbosa IC, Maia H, Coutinho E, Lopes R, Lopes AC, Noronha C et al. Effects of a single silastic contraceptive implant containing nomegestrol acetate (Uniplant) on endometrial morphology and ovarian function for 1 year. Contraception 2006; 74:492-497.
    • (57) Darney PD, Klaisle CM, Monroe SE, Cook CE, Phillips NR, Schindler A. Evaluation of a 1-year levonorgestrel-releasing contraceptive implant: side effects, release rates and biodegradability. Fertil Steril 1992; 58:137-143.
    • (58) Raymond EG, Singh M, Archer DF, Saxena BB, Baker J, Cole D. Contraceptive efficacy, pharmacokinetics and safety of Annuelle biodegradable norethindrone pellet implants. Fertil Steril 1996; 66:954-961.
    • (59) Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285:2347-2354.
    • (66) Kulier R, O'Brien P, Helmerhorst F, Usher-Patel M, d'Arcangues C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database of Syst Rev 2007; 4: CD005347.
    • (68) Wildemeersch D, Janssens D, Vrijens M, Weyers S. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine system. Contraception 2005; 71:465-469.
    • (70) Batár I. State-of-the-art of intrauterine contraception. European Journal of Contraception & Reproductive Health Care 2006; 11:262-269.
    • (71) Anonymous. WHO/CONRAD technical consultation on nonoxynol-9. Geneva: World Health Organisation; 2002.
    • (72) Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39:1-8.
    • (73) Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, Bax R. A randomized Phase I vaginal safety study of three concentrations of C31G vs. extra strength Gynol II. Contraception 2004; 70:233-240.
    • (74) van der Wijgert JHHM, Shattock RJ. Vaginal microbicides: moving ahead after an unexpected setback. AIDS 2007; 21:2369-2376.
    • (75) Amaral E, Perdigao A, Souza MH, Mauck C, Waller D, Zaneveld L et al. Vaginal safety after use of a bioadhesive acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception 2006; 73:542-547.
    • (76) Mauck CK, Weiner DH, Ballagh SA, Creinin MD, Archer DF, Schwartz JL et al. Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study. Contraception 2004; 70:77-83.
    • (77) Trottier S, Omar RF, Désormeaux A, Drouin J, Gagnon M-T, Vezina F et al. Safety, tolerance and acceptability of the Invisible Condom® and its vaginal applicator in healthy women and their sexual partners. Contraception 2007; 76:117-125.
    • (78) Barnhart KT, Rosenberg MJ, MacKay HT, Blithe DL, Higgins J, Walsh T et al. Contraceptive efficacy of a novel spermicidal microbicide used with a (79) Brache V, Croxatto H, Sitruk-Ware R, Maguire R, Montero JC, Kumar N et al. Effect of a single vaginal administration of levonorgestrel in Carraguard® gel on the ovulatory process: a potential candidate for "dual protection" emergency contraception. Contraception 2007; 76:111-116.
    • (92) Nichols M, Carter JF, Fylstra DL, Childers M. A comparative study of hysteroscopic sterilization performed in-office versus a hospital operating room. J Minim Invasive Gynecol 2006; 13:447-450.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article